NCT06510270View on ClinicalTrials.gov

Dapagliflozin in Reducing Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction

NANot yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

August 1, 2025

Study Completion Date

October 1, 2025

Conditions
Heart Failure with Preserved Ejection Fraction
Interventions
DRUG

Dapagliflozin 10 mg once daily

Dapagliflozin 10 mg once daily will be given to all patients in symptomstic heart failure group

DRUG

Loop diuretics

Loop diuretics (IV or orally) will be given to all patients in symptomatic heart failure group

DRUG

Treatments of associated co-morbidities (e.g Anti-hypertensive, oral hypoglycemic)

Treatment of associated co-morbidities will be given to both arms (group) such as anti-hypertensive (B blockers, ACIE, ARBS, CA channel blockers, Diuretics), oral hypoglycemic (Metformins, sulfonyl urea,.......)

All Listed Sponsors
lead

Aswan University

OTHER

NCT06510270 - Dapagliflozin in Reducing Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction | Biotech Hunter | Biotech Hunter